| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 83.7MM | +6% |
| Gross Profit | 65.2MM | - |
| Cost Of Revenue | 18.4MM | +10% |
| Operating Income | -178.3MM | +21% |
| Operating Expenses | 243.5MM | - |
| Net Income | -186.1MM | +17% |
| R&D | 137MM | +26% |
| G&A | 89.5MM | -1% |
| Amortization | 1.3MM | - |
| Interest Expense | 20.8MM | +2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first-quarter 2024 financial results on Thursday, May 9, 2024.
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the benchmark in the quarter. The small-cap growth universe revealed a stark dichotomy despite the positive performance of the benchmark Russell 2000 Growth Index, which […]
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego. Presentations will include late-breaking microbiologic data from the ARISE study of ARIKAYCE® (amikacin liposome inhalation suspension) in patien
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:
— New survey reveals the prevalence of "Unseenism," which can be described as a social phenomenon where gender and age biases can leave some patients feeling overlooked or unheard, in healthcare —
Insmed ( NASDAQ:INSM ) Full Year 2023 Results Key Financial Results Revenue: US$305.2m (up 24% from FY 2022). Net loss...
Insmed Incorporated (NASDAQ:INSM) Q4 2023 Earnings Call Transcript February 22, 2024 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.28 EPS, expectations were $-1.13. Insmed Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to […]
Q4 2023 Insmed Inc Earnings Call
Insmed (INSM) delivered earnings and revenue surprises of -13.27% and 0.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?